Biolargo, Inc.

BioLargo, Inc. is a U.S.-based developer and commercializer of environmental technologies, with operations spanning odor control, water treatment, and engineering services. The company sells CupriDyne Clean and related odor/VOC solutions through ONM Environmental, while its BEST subsidiary markets water-treatment technologies such as AEC for PFAS removal, AOS for micro-pollutants, and AROS for industrial water reuse. It also operates BLEST, an engineering business that provides air-quality compliance services and supports internal technology development. BioLargo’s business model combines product sales, service contracts, and technology commercialization, but it remains capital constrained and dependent on external financing to fund growth.

−189,4 %

43,9 %

−195,6 %

−56,3 %

1.01

0.95

— Biolargo, Inc.
%
Industrial odor and VOC solutions45% Odor-control chemicals, delivery systems, and related field services for landfills, wastewater, and municipal sanitation sites.
Private-label consumer odor products30% Third-party branded pet-odor and related odor-control products sold through private-label arrangements.
Water treatment technologies15% Proprietary technologies and equipment platforms for PFAS removal, micropollutant treatment, and water reuse.
Engineering and compliance services10% Air-quality control engineering, installation, maintenance, and compliance services delivered by BLEST.

BioLargo sells to a mix of municipal, industrial, government, and consumer-channel customers...

  • Municipal waste and sanitation operatorsprimary

    Cities, counties, landfills, and transfer stations buy odor-control products and installed systems to reduce nuisance odors and maintain compliance.

  • Private-label consumer brand partnersprimary

    Third-party brands buy odor-control formulations and packaging support, with Pooph historically driving a large share of consolidated revenue.

  • Government and defense facilitiessecondary

    U.S. Air Force bases buy ongoing air-quality control compliance services and related engineering work.

  • Industrial water-treatment customerssecondary

    Industrial users and project partners evaluate AEC, AOS, and AROS technologies for PFAS removal, micropollutant treatment, and reuse applications.

  • Internal development programssecondary

    BioLargo subsidiaries use BLEST engineering resources to advance proprietary technologies, especially PFAS and battery-related projects.

BioLargo is headquartered in the United States and its reported commercial activity is primarily domestic...

  • •United States is the core operating and revenue market
  • •Southern California is a key region for municipal odor-control contracts
  • •U.S. Air Force bases provide recurring nationwide engineering revenue
  • •Domestic focus reduces foreign-currency complexity but concentrates U.S. demand risk
  • •Technology commercialization and customer development are centered in the U.S.

BioLargo is trying to convert its technology portfolio into repeatable commercial revenue through a mix of product...

01
Commercialize PFAS and water-treatment technologiesmedium-term

Reference projects and early deployments are intended to validate the technology and unlock larger customer wins.

02
Expand recurring odor-control contractsshort-term

Recurring municipal and industrial service contracts provide more stable revenue than one-off product sales.

03
Broaden third-party distribution and private-label salesshort-term

Partner-led channels can scale revenue without requiring BioLargo to build a large internal sales force.

04
Conserve capital while scaling operationsshort-term

The company has limited liquidity and needs to fund growth without overextending its balance sheet.

BioLargo faces substantial going-concern and liquidity risk because operating cash flow has been negative and...

critical

Going-concern and funding risk

Management states that gross profits are not sufficient to fund current operations and that additional capital will be needed.

Scope
Corporate liquidity and ongoing R&D/commercialization spend
Materiality
high
high

Customer and product concentration

Pooph has represented a large portion of consolidated revenue, so a decline in that relationship can sharply reduce sales and operating income.

Scope
ONM Environmental and consolidated revenue mix
Materiality
high
high

Commercial adoption risk for PFAS technologies

New water-treatment technologies require validation, reference projects, and customer confidence before scaling.

Scope
AEC, AOS, and AROS commercialization
Materiality
high
high

Credit losses and collection risk

The company disclosed credit loss expense tied to customer contractual defaults and note receivable issues.

Scope
Receivables and note receivable balances
Materiality
high
medium

Execution and staffing constraints

Management notes the need for more qualified staff and reliance on contract manufacturers as demand grows.

Scope
Engineering delivery and product scaling
Materiality
medium
Revenue recognition timing
Can create large quarter-to-quarter swings in revenue and margin
Credit loss allowances
Can materially increase operating losses in affected periods
Derivative and warrant valuation
Can create non-cash expense and volatility in earnings and equity
Share-based compensation
Reduces cash outflow but increases non-cash compensation expense and dilution
Intersegment revenue elimination
Affects segment reporting and can obscure underlying external demand

BION ENVIRONMENTAL TECHNOLOGIES INC

BNET · Agricultural Chemicals

PERRIGO Co plc

PRGO · Pharmaceutical Preparations

CLOROX CO /DE/

CLX · Specialty Cleaning, Polishing and Sanitation Preparations

Emergent BioSolutions Inc.

EBS · Pharmaceutical Preparations

Beyond Air, Inc.

XAIR · Surgical & Medical Instruments & Apparatus

IMPACT BIOMEDICAL INC.

IBO · Pharmaceutical Preparations

: 11/08/2026